Abstract
Pulmonary fibrosis is a debilitating disease and is often fatal. It may be the consequence of direct lung injury or the result of genetic defects and occupational, environmental, or drug-related exposures. In many cases the etiology is unknown. The pathogenesis of all forms of pulmonary fibrosis regardless of type of injury or etiology is incompletely understood. These disorders are characterized by the accumulation of extracellular matrix in the lung interstitium with a loss of lung compliance and impaired gas exchange that ultimately leads to respiratory failure. Animal models of pulmonary fibrosis have become indispensable in the improved understanding of these disorders. Multiple models have been developed each with advantages and disadvantages. In this chapter we discuss the application of two of the most commonly employed direct lung instillation models, namely, the induction of pulmonary fibrosis with bleomycin or fluorescein isothiocyanate (FITC). We provide details on design, materials, and methods and describe how these models can be best undertaken. We also discuss methods to induce fibrosis in aged mice using murine gamma-herpesvirus (γHV-68) and approaches to exacerbate bleomycin- or FITC-induced fibrosis using γHV-68.
Key words
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ, Fibrosis AEJACoIP (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824. https://doi.org/10.1164/rccm.2009-040GL
Moore BB, Hogaboam CM (2008) Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294(2):L152–L160. https://doi.org/10.1152/ajplung.00313.2007
Moore BB, Lawson WE, Oury TD, Sisson TH, Raghavendran K, Hogaboam CM (2013) Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol 49(2):167–179. https://doi.org/10.1165/rcmb.2013-0094TR
Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, Burns L, Renteria L, Woods J, Chen L, Allard J, Ravindran P, Bitter H, Liang Z, Hogaboam CM, Kitson C, Budd DC, Fine JS, Bauer CM, Stevenson CS (2013) Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease. PLoS One 8(4):e59348. https://doi.org/10.1371/journal.pone.0059348
Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J (1997) Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 100(4):768–776. https://doi.org/10.1172/JCI119590
Lee CG, Cho SJ, Kang MJ, Chapoval SP, Lee PJ, Noble PW, Yehualaeshet T, Lu B, Flavell RA, Milbrandt J, Homer RJ, Elias JA (2004) Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis. J Exp Med 200(3):377–389. https://doi.org/10.1084/jem.20040104
Korfhagen TR, Swantz RJ, Wert SE, McCarty JM, Kerlakian CB, Glasser SW, Whitsett JA (1994) Respiratory epithelial cell expression of human transforming growth factor-alpha induces lung fibrosis in transgenic mice. J Clin Invest 93(4):1691–1699. https://doi.org/10.1172/JCI117152
Hardie WD, Korfhagen TR, Sartor MA, Prestridge A, Medvedovic M, Le Cras TD, Ikegami M, Wesselkamper SC, Davidson C, Dietsch M, Nichols W, Whitsett JA, Leikauf GD (2007) Genomic profile of matrix and vasculature remodeling in TGF-alpha induced pulmonary fibrosis. Am J Respir Cell Mol Biol 37(3):309–321. https://doi.org/10.1165/rcmb.2006-0455OC
Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, Senior RM, Elias JA (2001) Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 194(6):809–821
Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J (2001) Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 107(12):1529–1536. https://doi.org/10.1172/JCI12568
Sime PJ, Marr RA, Gauldie D, Xing Z, Hewlett BR, Graham FL, Gauldie J (1998) Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts. Am J Pathol 153(3):825–832
Sisson TH, Mendez M, Choi K, Subbotina N, Courey A, Cunningham A, Dave A, Engelhardt JF, Liu X, White ES, Thannickal VJ, Moore BB, Christensen PJ, Simon RH (2010) Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med 181(3):254–263. https://doi.org/10.1164/rccm.200810-1615OC
Pierce EM, Carpenter K, Jakubzick C, Kunkel SL, Flaherty KR, Martinez FJ, Hogaboam CM (2007) Therapeutic targeting of CC ligand 21 or CC chemokine receptor 7 abrogates pulmonary fibrosis induced by the adoptive transfer of human pulmonary fibroblasts to immunodeficient mice. Am J Pathol 170(4):1152–1164. https://doi.org/10.2353/ajpath.2007.060649
Trujillo G, Meneghin A, Flaherty KR, Sholl LM, Myers JL, Kazerooni EA, Gross BH, Oak SR, Coelho AL, Evanoff H, Day E, Toews GB, Joshi AD, Schaller MA, Waters B, Jarai G, Westwick J, Kunkel SL, Martinez FJ, Hogaboam CM (2010) TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis. Sci Transl Med 2(57):57ra82. https://doi.org/10.1126/scitranslmed.3001510
Blackwell TS, Tager AM, Borok Z, Moore BB, Schwartz DA, Anstrom KJ, Bar-Joseph Z, Bitterman P, Blackburn MR, Bradford W, Brown KK, Chapman HA, Collard HR, Cosgrove GP, Deterding R, Doyle R, Flaherty KR, Garcia CK, Hagood JS, Henke CA, Herzog E, Hogaboam CM, Horowitz JC, King TE Jr, Loyd JE, Lawson WE, Marsh CB, Noble PW, Noth I, Sheppard D, Olsson J, Ortiz LA, O’Riordan TG, Oury TD, Raghu G, Roman J, Sime PJ, Sisson TH, Tschumperlin D, Violette SM, Weaver TE, Wells RG, White ES, Kaminski N, Martinez FJ, Wynn TA, Thannickal VJ, Eu JP (2014) Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med 189(2):214–222. https://doi.org/10.1164/rccm.201306-1141WS
Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, Lasky JA, Loyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunninghake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kondoh Y, Lynch DA, Muller-Quernheim J, Myers JL, Nicholson AG, Selman M, Toews GB, Wells AU, Martinez FJ, Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators (2007) Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176(7):636–643. https://doi.org/10.1164/rccm.200703-463PP
Fell CD, Martinez FJ, Liu LX, Murray S, Han MK, Kazerooni EA, Gross BH, Myers J, Travis WD, Colby TV, Toews GB, Flaherty KR (2010) Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 181(8):832–837. https://doi.org/10.1164/rccm.200906-0959OC
Geifman N, Rubin E (2013) The mouse age phenome knowledgebase and disease-specific inter-species age mapping. PLoS One 8(12):e81114. https://doi.org/10.1371/journal.pone.0081114
Fox JG, Barthold S, Davisson M, Newcomer C, Quimby F, Smith A (2007) The mouse in aging research, 2nd edn. American College Laboratory Animal Medicine, Burlington, MA, pp 637–672
Redente EF, Jacobsen KM, Solomon JJ, Lara AR, Faubel S, Keith RC, Henson PM, Downey GP, Riches DW (2011) Age and sex dimorphisms contribute to the severity of bleomycin-induced lung injury and fibrosis. Am J Physiol Lung Cell Mol Physiol 301(4):L510–L518. https://doi.org/10.1152/ajplung.00122.2011
Stout-Delgado HW, Cho SJ, Chu SG, Mitzel DN, Villalba J, El-Chemaly S, Ryter SW, Choi AM, Rosas IO (2016) Age-dependent susceptibility to pulmonary fibrosis is associated with NLRP3 inflammasome activation. Am J Respir Cell Mol Biol 55(2):252–263. https://doi.org/10.1165/rcmb.2015-0222OC
Sueblinvong V, Neujahr DC, Mills ST, Roser-Page S, Ritzenthaler JD, Guidot D, Rojas M, Roman J (2012) Predisposition for disrepair in the aged lung. Am J Med Sci 344(1):41–51. https://doi.org/10.1097/MAJ.0b013e318234c132
Sueblinvong V, Neveu WA, Neujahr DC, Mills ST, Rojas M, Roman J, Guidot DM (2014) Aging promotes pro-fibrotic matrix production and increases fibrocyte recruitment during acute lung injury. Adv Biosci Biotechnol 5(1):19–30. https://doi.org/10.4236/abb.2014.51004
Naik PN, Horowitz JC, Moore TA, Wilke CA, Toews GB, Moore BB (2012) Pulmonary fibrosis induced by gamma-herpesvirus in aged mice is associated with increased fibroblast responsiveness to transforming growth factor-beta. J Gerontol A Biol Sci Med Sci 67(7):714–725. https://doi.org/10.1093/gerona/glr211
Torres-Gonzalez E, Bueno M, Tanaka A, Krug LT, Cheng DS, Polosukhin VV, Sorescu D, Lawson WE, Blackwell TS, Rojas M, Mora AL (2012) Role of endoplasmic reticulum stress in age-related susceptibility to lung fibrosis. Am J Respir Cell Mol Biol 46(6):748–756. https://doi.org/10.1165/rcmb.2011-0224OC
McMillan TR, Moore BB, Weinberg JB, Vannella KM, Fields WB, Christensen PJ, van Dyk LF, Toews GB (2008) Exacerbation of established pulmonary fibrosis in a murine model by gammaherpesvirus. Am J Respir Crit Care Med 177(7):771–780. https://doi.org/10.1164/rccm.200708-1184OC
Umezawa H, Maeda K, Takeuchi T, Okami Y (1966) New antibiotics, bleomycin A and B. J Antibiot 19(5):200–209
Schein PS, VT DV Jr, Hubbard S, Chabner BA, Canellos GP, Berard C, Young RC (1976) Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med 85(4):417–422
Suzuki Y, Miyake H, Sakai M, Inuyama Y, Matsukawa J (1969) Bleomycin in malignant tumors of head and neck. Keio J Med 18(3):153–162
Oka S, Sato K, Nakai Y, Kurita K, Hashimoto K, Oshibe M (1969) Treatment of lung cancer with bleomycin. The science reports of the research institutes, Tohoku University Ser C, Medicine. Tohoku Daigaku 16 (1):30–36
Clinical Screening Co-operative Group of the European Organization for Research on the Treatment of Cancer (1970) Study of the clinical efficiency of bleomycin in human cancer. Br Med J 2(5710):643–645
O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A (2003) Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 14(1):91–96
Sleijfer S (2001) Bleomycin-induced pneumonitis. Chest 120(2):617–624
Huang CH, Mirabelli CK, Jan Y, Crooke ST (1981) Single-strand and double-strand deoxyribonucleic acid breaks produced by several bleomycin analogues. Biochemistry 20(2):233–238
Tounekti O, Kenani A, Foray N, Orlowski S, Mir LM (2001) The ratio of single- to double-strand DNA breaks and their absolute values determine cell death pathway. Br J Cancer 84(9):1272–1279. https://doi.org/10.1054/bjoc.2001.1786
Sugiura Y, Kikuchi T (1978) Formation of superoxide and hydroxy radicals in iron(II)-bleomycin-oxygen system: electron spin resonance detection by spin trapping. J Antibiot 31(12):1310–1312
Liu LV, Bell CB 3rd, Wong SD, Wilson SA, Kwak Y, Chow MS, Zhao J, Hodgson KO, Hedman B, Solomon EI (2010) Definition of the intermediates and mechanism of the anticancer drug bleomycin using nuclear resonance vibrational spectroscopy and related methods. Proc Natl Acad Sci U S A 107(52):22419–22424. https://doi.org/10.1073/pnas.1016323107
Decker A, Chow MS, Kemsley JN, Lehnert N, Solomon EI (2006) Direct hydrogen-atom abstraction by activated bleomycin: an experimental and computational study. J Am Chem Soc 128(14):4719–4733. https://doi.org/10.1021/ja057378n
Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R (2002) Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol 83(3):111–119
Kumar RK, Watkins SG, Lykke AW (1985) Pulmonary responses to bleomycin-induced injury: an immunomorphologic and electron microscopic study. Exp Pathol 28(1):33–43
Roberts SN, Howie SE, Wallace WA, Brown DM, Lamb D, Ramage EA, Donaldson K (1995) A novel model for human interstitial lung disease: hapten-driven lung fibrosis in rodents. J Pathol 176(3):309–318. https://doi.org/10.1002/path.1711760313
Christensen PJ, Goodman RE, Pastoriza L, Moore B, Toews GB (1999) Induction of lung fibrosis in the mouse by intratracheal instillation of fluorescein isothiocyanate is not T-cell-dependent. Am J Pathol 155(5):1773–1779. https://doi.org/10.1016/S0002-9440(10)65493-4
Fleischman RW, Baker JR, Thompson GR, Schaeppi UH, Illievski VR, Cooney DA, Davis RD (1971) Bleomycin-induced interstitial pneumonia in dogs. Thorax 26(6):675–682
Organ L, Bacci B, Koumoundouros E, Barcham G, Milne M, Kimpton W, Samuel C, Snibson K (2015) Structural and functional correlations in a large animal model of bleomycin-induced pulmonary fibrosis. BMC Pulm Med 15:81. https://doi.org/10.1186/s12890-015-0071-6
Snider GL, Hayes JA, Korthy AL (1978) Chronic interstitial pulmonary fibrosis produced in hamsters by endotracheal bleomycin: pathology and stereology. Am Rev Respir Dis 117(6):1099–1108. https://doi.org/10.1164/arrd.1978.117.6.1099
Thrall RS, McCormick JR, Jack RM, McReynolds RA, Ward PA (1979) Bleomycin-induced pulmonary fibrosis in the rat: inhibition by indomethacin. Am J Pathol 95(1):117–130
Williams KJ, Robinson NE, Lim A, Brandenberger C, Maes R, Behan A, Bolin SR (2013) Experimental induction of pulmonary fibrosis in horses with the gammaherpesvirus equine herpesvirus 5. PLoS One 8(10):e77754. https://doi.org/10.1371/journal.pone.0077754
Miele A, Dhaliwal K, Du Toit N, Murchison JT, Dhaliwal C, Brooks H, Smith SH, Hirani N, Schwarz T, Haslett C, Wallace WA, McGorum BC (2014) Chronic pleuropulmonary fibrosis and elastosis of aged donkeys: similarities to human pleuroparenchymal fibroelastosis. Chest 145(6):1325–1332. https://doi.org/10.1378/chest.13-1306
Williams K, Malarkey D, Cohn L, Patrick D, Dye J, Toews G (2004) Identification of spontaneous feline idiopathic pulmonary fibrosis: morphology and ultrastructural evidence for a type II pneumocyte defect. Chest 125(6):2278–2288
Corcoran BM, Cobb M, Martin MW, Dukes-McEwan J, French A, Fuentes VL, Boswood A, Rhind S (1999) Chronic pulmonary disease in West Highland white terriers. Vet Rec 144(22):611–616
Adamson IY, Bowden DH (1974) The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 77(2):185–197
McCullough B, Collins JF, Johanson WG Jr, Grover FL (1978) Bleomycin-induced diffuse interstitial pulmonary fibrosis in baboons. J Clin Invest 61(1):79–88. https://doi.org/10.1172/JCI108928
Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C, Wilke CA, Toews GB (2005) CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol 166(3):675–684. https://doi.org/10.1016/S0002-9440(10)62289-4
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
O’Dwyer, D.N., Moore, B.B. (2018). Animal Models of Pulmonary Fibrosis. In: Alper, S., Janssen, W. (eds) Lung Innate Immunity and Inflammation. Methods in Molecular Biology, vol 1809. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8570-8_24
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8570-8_24
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8569-2
Online ISBN: 978-1-4939-8570-8
eBook Packages: Springer Protocols